Reduced Stimulant Use Linked to Improvement in Indicators of Recovery
16 Jan 2024
Clinical Result
TUESDAY, Jan. 16, 2024 -- For individuals with stimulant use disorder, reduced stimulant use is associated with improvement in clinical indicators of recovery, according to a study published online Jan. 10 in Addiction.
Masoumeh Aminesmaeili, Ph.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder in a secondary analysis of a pooled dataset of 13 RCTs. The trials included 2,062 individuals seeking treatment for cocaine or methamphetamine use disorders. Reduced stimulant use was validated against a set of clinical indicators.
The researchers found that more of the participants reduced the frequency of primary drug use than achieved abstinence (18.0 versus 14.2 percent, respectively). Significant associations were seen for reduced use with decreases in craving for the primary drug, drug-seeking behaviors, and depression severity (60.1, 41.0, and 39.9 percent, respectively) and in multiple measures of global improvement in psychosocial functioning and severity of drug-related problems, although less strongly than abstinence. Sustained clinical benefit at follow-up was seen in association with reduced use, as confirmed by negative urine tests (adjusted odds ratio, 0.50 for reduced use versus no reduction in use).
"This study provides evidence that reducing the overall use of drugs is important and clinically meaningful. This shift may open opportunities for medication development that can help individuals achieve these improved outcomes, even if complete abstinence is not immediately achievable or wanted," coauthor Mehdi Farokhnia, M.D., M.P.H., also from Johns Hopkins Bloomberg School of Public Health, said in a statement.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.